Transpire Bio Strengthens Leadership Team with New Appointments to Lead Commercialization, Quality Assurance, and Manufacturing

News Transpire Bio Strengthens Leadership Team with New Appointments to Lead Commercialization, Quality Assurance, and Manufacturing WESTON, Fla., Oct. 15, 2024 (GLOBE NEWSWIRE) Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced the addition of three distinguished biopharma industry executives to its leadership team. Joining […]

Transpire Bio Achieves Important Corporate Milestone with Completion of First Human Subject Study in the Company’s Asthma and Chronic Obstructive Pulmonary Disease Inhaled Drug Program

News WESTON, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) Transpire Bio, an integrated, clinical-stage biopharmaceutical company focused on developing inhaled medicines, today announced that the company has completed the first human subject study of its inhalation product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). According to statistics from the World Health Organization, […]

Transpire Bio Expands Access and Innovation in Inhalation Therapies with New Research and Manufacturing Facility

News Transpire Bio Expands Access and Innovation in Inhalation Therapies with New Research and Manufacturing Facility WESTON, Fla., October 30, 2023 (PR NEWSWIRE) — Transpire Bio, a development-stage biopharmaceutical company, was joined by local and state elected officials and industry leaders to celebrate the opening of its new research facility and global headquarters in Weston. […]

Transpire Bio announces agreement with INTO for the development of three inhaled medicines

News Transpire Bio announces agreement with INTO for the development of three inhaled medicines WESTON, Fla., July 7, 2025 (GLOBE NEWSWIRE) Transpire Bio, a development-stage pharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, has today announced a definitive agreement with INTO (Inhalation Together) to develop TRB-5, TRB-6 and TRB-7, inhaled medicines […]